相关临床试验
22
5 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
5
22.7%
已完成
6
27.3%
招募中
1
4.5%
终止
8
36.4%
撤回
2
9.1%
暂无批准数据
- Arbutus Biopharma has reacquired Greater China rights to imdusiran from Qilu Pharmaceutical, regaining global control of the hepatitis B RNAi therapeutic. - The company's imdusiran has achieved functional cure in eight patients across Phase 2a trials, with two patients cured without interferon treatment. - Arbutus has established a Scientific Advisory Board featuring five globally recognized hepatitis B experts to guide late-stage clinical development strategy. - The RNAi therapeutic targets hepatitis B surface antigen reduction to reawaken immune system control of the virus in chronic hepatitis B patients.
- A Phase 2a trial shows that imdusiran, VTP-300, and low-dose nivolumab led to significantly greater HBsAg declines in chronic hepatitis B patients. - 23% of participants receiving the combination therapy achieved HBsAg loss by Week 48, indicating a potential path to functional cure. - The triple combination was generally well-tolerated, with no immune-related adverse events reported during the study period. - These findings support the strategy of combining surface antigen reduction with immune reawakening in HBV treatment.
